Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in ...

Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including DexCom ...

An international study co-led by University of Calgary researchers has found new insulin delivery technology helps control glucose levels during pregnancy for those with Type 1 diabetes, which is ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

Now, it’s worth noting Stock Advisor's total average return is 1,064% — a market-crushing outperformance compared to 194% for ...

According to Diabète Québec, type 2 diabetes is the most common form, affecting nearly 90% of those living with diabetes, and many eventually require insulin when lifestyle changes and oral ...

Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...

The global patient monitoring devices market size is expected to reach USD 118.21 billion by 2033, registering a CAGR of 10.21% from 2025 to 2033, according to a new report by Grand View Research, Inc ...

The CGM market is expected to experience double-digit percentage growth over the next five years, reaching nearly $29 billion ...

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous monitoring system app, leading the FDA to issue its most serious recall notice. | Dexcom has been hit by a major ...

The world's largest online retailer got a lift from its booming cloud computing business on Friday, Oct. 31, 2025, while a soft sales outlook weighed on a medical device firm's stock.